Xiao Yan, Li Jun-Dong, Shi Hong-Liu, Liu Ji-Hong, Feng Yan-Ling, Li Meng-Da
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China.
Ai Zheng. 2007 Apr;26(4):386-9.
BACKGROUND & OBJECTIVE: In recent years, the neoadjuvant chemotherapy for cervical cancer has evoked more and more attention and has been used widely. But the chemosensitivity of individuals to various antitumor drugs is different. This study was to investigate the chemosensitivity of cervical cancer cells to antitumor drugs using in vitro MTT assay chemosensitivity test.
The sensitivity of fresh human cervical cancer cells from 32 patients to 9 cytotoxic drugs was tested using in vitro MTT assay.
The cytotoxic activities of the 9 drugs for cervical cancer were in sequence from high to low as follows: liposomal paclitaxel, taxol, carboplatin (CBP), ifosfamide (IFO), etoposide (VP-16), 5-fluorouracil (5-FU), cisplatin (DDP), bleomycin (BLM), and cyclophosphamide (CTX). Generally, cervical cancer cells were more sensitive to paclitaxel, taxol, and CBP than to other drugs (P<0.05) with inhibition rates of 56.56%, 55.66%, and 46.81%, respectively. Stage Ib1 cervical cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 58.71%, 53.00%, and 49.25%, respectively; stage Ib2 cervical cancer cells were more sensitive to paclitaxel and taxol than to other drugs with inhibition rates of 65.26% and 50.06%. Both moderately and poorly differentiated squamous cell cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 52.01%, 49.21%, and 40.02% for the former, and 60.02%, 61.16%, and 48.75% for the latter.
MTT assay, a sensitive and widely used chemosensitivity testing method, is helpful in sensitive drug screening and neoadjuvant chemotherapy regimen selection for cervical cancer. Cervical cancer cells are more sensitive to paclitaxel, taxol, and CBP than to other tested drugs in this study.
近年来，宫颈癌新辅助化疗越来越受到关注并得到广泛应用。但个体对各种抗肿瘤药物的化疗敏感性存在差异。本研究采用体外MTT法化疗敏感性试验，探讨宫颈癌细胞对抗肿瘤药物的化疗敏感性。
采用体外MTT法检测32例患者新鲜宫颈癌细胞对9种细胞毒性药物的敏感性。
9种药物对宫颈癌的细胞毒活性从高到低依次为：脂质体紫杉醇、紫杉醇、卡铂（CBP）、异环磷酰胺（IFO）、依托泊苷（VP-16）、5-氟尿嘧啶（5-FU）、顺铂（DDP）、博来霉素（BLM）和环磷酰胺（CTX）。总体而言，宫颈癌细胞对紫杉醇、脂质体紫杉醇和卡铂的敏感性高于其他药物（P<0.05），抑制率分别为56.56%、55.66%和46.81%。Ib1期宫颈癌细胞对紫杉醇、脂质体紫杉醇和卡铂的敏感性高于其他药物，抑制率分别为58.71%、53.00%和49.25%；Ib2期宫颈癌细胞对脂质体紫杉醇和紫杉醇的敏感性高于其他药物，抑制率分别为65.26%和50.06%。中、低分化鳞状细胞癌细胞对紫杉醇、脂质体紫杉醇和卡铂的敏感性均高于其他药物，前者的抑制率分别为52.01%、49.21%和40.02%，后者分别为60.02%、61.16%和48.75%。
MTT法是一种敏感且广泛应用的化疗敏感性检测方法，有助于宫颈癌敏感药物筛选和新辅助化疗方案的选择。在本研究中，宫颈癌细胞对紫杉醇、脂质体紫杉醇和卡铂的敏感性高于其他受试药物。
